

PUBLICATIONS

(* = first author or co-first author; § = corresponding author)

1. **Degiacomi G**, Chiarelli LR, Recchia D, Petricci E, Gianibbi B, Fiscarelli EV, Fattorini L, Manetti F, Pasca MR. The Antimalarial Mefloquine Shows Activity against *Mycobacterium abscessus*, Inhibiting Mycolic Acid Metabolism. *Int J Mol Sci*. 2021. 22:8533.
2. Farjallah A, Chiarelli LR, Forbak M, **Degiacomi G**, Danel M, Goncalves F, Carayon C, Seguin C, Fumagalli M, Záhorszka M, Vega E, Abid S, Grzegorzewicz A, Jackson M, Peixoto A, Korduláková J, Pasca MR, Lherbet C, Chassaing S. A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in *Mycobacterium tuberculosis*. **ACS Infect Dis**. 2021. 7:552-565.
3. Monakhova N, Korduláková J, Vocat A, Egorova A, Lepioshkin A, Salina EG, Nosek J, Repková E, Zemanová J, Jurdáková H, Górová R, Roh J, **Degiacomi G**, Sammartino JC, Pasca MR, Cole ST, Mikušová K, Makarov V. Design and Synthesis of Pyrano[3,2-b] indolones Showing Antimycobacterial Activity. **ACS Infect Dis**. 2021. 7:88-100.
4. Hsu H, Boudova S, Mvula G, Divala TH, Rach D, Mungwira RG, Boldrin F, **Degiacomi G**, Manganelli R, Laufer MK, Cairo C. Age-related changes in PD-1 expression coincide with increased cytotoxic potential in Vδ2 T cells during infancy. **Cell Immunol**. 2021. 359:104244.
5. Chiarelli LR*, **Degiacomi G***, Egorova A, Makarov V, Pasca MR. Nitric oxide-releasing compounds for the treatment of lung infections. **Drug Discov Today**. 2021. 26:542-550.
6. **Degiacomi G***§, Sammartino JC, Sinigiani V, Marra P, Urbani A, Pasca MR§. In vitro Study of Bedaquiline Resistance in *Mycobacterium tuberculosis* Multi-Drug Resistant Clinical Isolates. **Front Microbiol**. 2020. 11:559469. §co-corresponding author
7. Mori G, Orena BS, Chiarelli LR, **Degiacomi G**, Sammartino JC, Guerin M, Makarov V, Riccardi G, Pasca MR. Rv0579 is involved in the resistance to the TP053 antitubercular prodrug. **Front Microbiol**. 2020. 11:292.
8. **Degiacomi G***, Belardinelli JM, Pasca MP, De Rossi E, Riccardi G, Chiarelli LR. Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3. **Appl Sci**. 2020. 10, 623.
9. Rodriguez F, Saffon N, Sammartino JC, **Degiacomi G**, Pasca MR, Lherbet C. First triclosan-based macrocyclic inhibitors of InhA enzyme. **Bioorg Chem**. 2020. 95:103498.
10. Chiarelli LR, Salina E, Mori G, Azhikina T, Riabova O, Lepioshkin A, Grigorov A, Forbak M, Madacki J, Orena B, Manfredi M, Gosetti Fabio, Buzzi A, **Degiacomi G**, Sammartino JC, Marengo E, Korduláková J, Riccardi G, Mikušová K, Makarov V, Pasca MR. New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053. **ACS Infect Dis**. 2020. 6:313-323.
11. **Degiacomi G***, Sammartino JC, Chiarelli LR, Makarov V, Pasca MR. *Mycobacterium abscessus*, an emerging and worrisome pathogen among cystic fibrosis patients. **Int J Mol Sci**. 2019. 20: 5868.
12. Chiarelli LR, Mori G, Orena BS, Esposito M, Lane T, de Jesus Lopes Ribeiro AL, **Degiacomi G**, Zemanová J, Szádocka S, Huszár S, Palčeková Z, Manfredi M, Gosetti F, Lelièvre J, Ballell L, Kazakova E, Makarov V, Marengo E, Mikusova K, Cole ST, Riccardi G, Ekins S, Pasca MR. A multitarget approach to drug discovery inhibiting *Mycobacterium tuberculosis* PyrG and PanK. **Sci Rep**. 2018 8:3187.
13. Boldrin F*, **Degiacomi G***, Serafini A, Kolly G, Ventura M, Sala C, Provvedi R, Palù G, Cole S, Manganelli R. Promoter mutagenesis for fine tuning expression of essential genes in *Mycobacterium tuberculosis*. **Microb Biotechnol**. 2017. doi: 10.1111/1751-7915.12875.

14. Rosado LA*, Wahni K*, **Degiacomi G***, Pedre B, Young D, G de la Rubia A, Boldrin F, Martens E, Marcos-Pascual L, Sancho-Vaello E, Albesa-Jové D, Provvedi R, Martin C, Makarov V, Versées W, Verniest G, Guerin ME, Mateos LM, Manganelli R, Messens J. The antibacterial prodrug activator Rv2466c is a mycothiol-dependent reductase in the oxidative stress response of *Mycobacterium tuberculosis*. **J Biol Chem**. 2017. pii: jbc.M117.797837.
15. Rieck B*, **Degiacomi G***, Zimmermann M*, Cascioferro A*, Boldrin F, Lazar-Adler NR, Bottrill AR, le Chevalier F, Frigui W, Bellinzoni M, Lisa MN, Alzari PM, Nguyen L, Brosch R, Sauer U, Manganelli R, O'Hare HM. PknG senses amino acid availability to control metabolism and virulence of *Mycobacterium tuberculosis*. **PLoS Pathog**. 2017. 13: e1006399.
16. Esposito M, Szadocka S, **Degiacomi G**, Orena BS, Mori G, Piano V, Boldrin F, Zemanová J, Huszár S, Barros D, Ekins S, Lelièvre J, Manganelli R, Mattevi A, Pasca MR, Riccardi G, Balzell L, Mikušová K, Chiarelli LR. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors. **ACS Infect Dis**. 2017. 3: 428-437.
17. **Degiacomi G***, Benjak A, Madacki J, Boldrin F, Provvedi R, Palù G, Kordulakova J, Cole ST, Manganelli R. Essentiality of *mmpL3* and impact of its silencing on *Mycobacterium tuberculosis* gene expression. **Sci Rep**. 2017. 7:43495.
18. **Degiacomi G***, Personne Y, Mondésert G, Ge X, Mandava CS, Hartkoorn RC, Boldrin F, Goel P, Peisker K, Benjak A, Barrio MB, Ventura M, Brown AC, Leblanc V, Bauer A, Sanyal S, Cole ST, Lagrange S, Parish T, Manganelli R. Micrococcin P1 - A bactericidal thiopeptide active against *Mycobacterium tuberculosis*. **Tuberculosis**, 2016. 100: 95-101.
19. Mori G, Chiarelli LR, Esposito M, Makarov V, Bellinzoni M, Hartkoorn RC, **Degiacomi G**, Boldrin F, Ekins S, de Jesus Lopes Ribeiro AL, Marino LB, Centárová I, Svetlíková Z, Blaško J, Kazakova E, Lepioshkin A, Barilone N, Zanoni G, Porta A, Fondi M, Fani R, Baulard AR, Mikušová K, Alzari PM, Manganelli R, de Carvalho LP, Riccardi G, Cole ST, Pasca MR. Thiophenecarboxamide Derivatives Activated by EthA Kill *Mycobacterium tuberculosis* by Inhibiting the CTP Synthetase PyrG. **Chem Biol**. 2015. 22: 917-927.
20. Tantry SJ*, **Degiacomi G***, Sharma S*, Jena LK, Narayan A, Guptha S, Shanbhag G, Menasinakai S, Mallya M, Awasthy D, Balakrishnan G, Kaur P, Bhattacharjee D, Narayan C, Reddy J, Naveen Kumar CN, Shandil R, Boldrin F, Ventura M, Manganelli R, Hartkoorn RC, Cole ST, Panda M, Markad SD, Ramachandran V, Ghorpade SR, Dinesh N. Whole cell screen based identification of spiropiperidines with potent antitubercular properties. **Bioorg Med Chem Lett**. 2015. 25: 3234-3245.
21. Boldrin F, Ventura M, **Degiacomi G**, Ravishankar S, Sala C, Svetlikova Z, Ambady A, Dhar N, Kordulakova J, Zhang M, Serafini A, Vishwas KG, Kolly GS, Kumar N, Palù G, Guerin ME, Mikusova K, Cole ST, Manganelli R. The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for *Mycobacterium tuberculosis* growth *in vitro* and *in vivo*. **J Bacteriol**. 2014. 196: 3441-3451.
22. Ventura M, Rieck B, Boldrin F, **Degiacomi G**, Bellinzoni M, Barilone N, Alzaidi F, Alzari PM, Manganelli R, O'Hare HM. GarA is an essential regulator of metabolism in *Mycobacterium tuberculosis*. **Mol Microbiol**. 2013. 90: 356-366.
23. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Röttger S, Buroni S, Fullam E, **Degiacomi G**, Lucarelli AP, Read RJ, Zanoni G, Edmondson DE, De Rossi E, Pasca MR, McKinney JD, Dyson PJ, Riccardi G, Mattevi A, Cole ST, Binda C. Structural basis for benzothiazinone-mediated killing of *Mycobacterium tuberculosis*. **Sci Transl Med**. 2012. 5: 150ra121.
24. Ribeiro AL*, **Degiacomi G***, Ewann F, Buroni S, Incandela ML, Chiarelli LR, Mori G, Kim J, Contreras-Dominguez M, Park YS, Han SJ, Brodin P, Valentini G, Rizzi M, Riccardi G, Pasca MR. Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in *Mycobacterium smegmatis*. **PLoS One**, 2011. 6: e26675.

25. Manina G, Bellinzoni M, Pasca MR, Neres J, Milano A, Ribeiro AL, Buroni S, Skovierová H, Dianišková P, Mikušová K, Marák J, Makarov V, Giganti D, Haouz A, Lucarelli AP, **Degiacomi G**, Piazza A, Chiarelli LR, De Rossi E, Salina E, Cole ST, Alzari PM, Riccardi G. Biological and structural characterization of the *Mycobacterium smegmatis* nitroreductase NfnB, and its role in benzothiazinone resistance. **Mol Microbiol.** 2010. 77: 1172-1185.
26. Pasca MR, **Degiacomi G**, Ribeiro AL, Zara F, De Mori P, Heym B, Mirrione M, Berra R, Pagani L, Pucillo L, Troupioti P, Makarov V, Cole ST, Riccardi G. Clinical isolates of *Mycobacterium tuberculosis* in four European hospitals are uniformly susceptible to benzothiazinones. **Antimicrob Agents Chemother.** 2010. 54: 1616-1618.